$37.78
-0.42[-1.10%]
Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here
Get Real Time Here
$37.78
0[0.00%]
| Open- | Close- |
| Vol / Avg.0 / 982.036K | Mkt Cap4.984B |
| Day Range- - - | 52 Wk Range29.850 - 59.450 |
Halozyme Therapeutics Stock (NASDAQ:HALO), Key Statistics
Halozyme Therapeutics Stock (NASDAQ: HALO) analysis, key statistics.
Valuation Measures
Enterprise Value
6.2B
Trailing P/E
22.48
Forward P/E
9.43
PE Ratio (TTM)
22.87
PEG Ratio (TTM)
- -
Price / Sales (ttm)
6.8
Price / Book (mrq)
33.37
Price / EBITDA
13.54
Enterprise Value / EBITDA (TTM)
15.93
Earnings Yield
4.45%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
1.14
Tangible Book value per share
-5.89
Total Liabilities (Quarterly)
1.7B
Total Assets
1.8B
Total Liabilities
1.7B
Profitability
Net income Growth
2.3
Gross Margin
77.35%
Net Margin
33.82%
EBIT Margin
44.18%
EBITDA Margin
53.51%
Operating Margin
42.73%
Halozyme Therapeutics Stock (NASDAQ:HALO), Key Statistics
Halozyme Therapeutics Stock (NASDAQ: HALO) analysis, key statistics.
Valuation Measures
Enterprise Value
6.2B
Trailing P/E
22.48
Forward P/E
9.43
PE Ratio (TTM)
22.87
PEG Ratio (TTM)
- -
Price / Sales (ttm)
6.8
Price / Book (mrq)
33.37
Price / EBITDA
13.54
Enterprise Value / EBITDA (TTM)
15.93
Earnings Yield
4.45%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
1.14
Tangible Book value per share
-5.89
Total Liabilities (Quarterly)
1.7B
Total Assets
1.8B
Total Liabilities
1.7B
Profitability
Net income Growth
2.3
Gross Margin
77.35%
Net Margin
33.82%
EBIT Margin
44.18%
EBITDA Margin
53.51%
Operating Margin
42.73%
Halozyme Therapeutics Stock (NASDAQ:HALO), Key Statistics
Halozyme Therapeutics Stock (NASDAQ: HALO) analysis, key statistics.
Valuation Measures
Enterprise Value
6.2B
Trailing P/E
22.48
Forward P/E
9.43
PE Ratio (TTM)
22.87
PEG Ratio (TTM)
- -
Price / Sales (ttm)
6.8
Price / Book (mrq)
33.37
Price / EBITDA
13.54
Enterprise Value / EBITDA (TTM)
15.93
Earnings Yield
4.45%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
1.14
Tangible Book value per share
-5.89
Total Liabilities (Quarterly)
1.7B
Total Assets
1.8B
Total Liabilities
1.7B
Profitability
Net income Growth
2.3
Gross Margin
77.35%
Net Margin
33.82%
EBIT Margin
44.18%
EBITDA Margin
53.51%
Operating Margin
42.73%
Halozyme Therapeutics Stock (NASDAQ:HALO), Key Statistics
Halozyme Therapeutics Stock (NASDAQ: HALO) analysis, key statistics.
Valuation Measures
Enterprise Value
6.2B
Trailing P/E
22.48
Forward P/E
9.43
PE Ratio (TTM)
22.87
PEG Ratio (TTM)
- -
Price / Sales (ttm)
6.8
Price / Book (mrq)
33.37
Price / EBITDA
13.54
Enterprise Value / EBITDA (TTM)
15.93
Earnings Yield
4.45%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
1.14
Tangible Book value per share
-5.89
Total Liabilities (Quarterly)
1.7B
Total Assets
1.8B
Total Liabilities
1.7B
Profitability
Net income Growth
2.3
Gross Margin
77.35%
Net Margin
33.82%
EBIT Margin
44.18%
EBITDA Margin
53.51%
Operating Margin
42.73%
Halozyme Therapeutics Stock (NASDAQ:HALO), Key Statistics
Halozyme Therapeutics Stock (NASDAQ: HALO) analysis, key statistics.
Valuation Measures
Enterprise Value
6.2B
Trailing P/E
22.48
Forward P/E
9.43
PE Ratio (TTM)
22.87
PEG Ratio (TTM)
- -
Price / Sales (ttm)
6.8
Price / Book (mrq)
33.37
Price / EBITDA
13.54
Enterprise Value / EBITDA (TTM)
15.93
Earnings Yield
4.45%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
1.14
Tangible Book value per share
-5.89
Total Liabilities (Quarterly)
1.7B
Total Assets
1.8B
Total Liabilities
1.7B
Profitability
Net income Growth
2.3
Gross Margin
77.35%
Net Margin
33.82%
EBIT Margin
44.18%
EBITDA Margin
53.51%
Operating Margin
42.73%
Halozyme Therapeutics Stock (NASDAQ:HALO), Key Statistics
Halozyme Therapeutics Stock (NASDAQ: HALO) analysis, key statistics.
Valuation Measures
Enterprise Value
6.2B
Trailing P/E
22.48
Forward P/E
9.43
PE Ratio (TTM)
22.87
PEG Ratio (TTM)
- -
Price / Sales (ttm)
6.8
Price / Book (mrq)
33.37
Price / EBITDA
13.54
Enterprise Value / EBITDA (TTM)
15.93
Earnings Yield
4.45%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
1.14
Tangible Book value per share
-5.89
Total Liabilities (Quarterly)
1.7B
Total Assets
1.8B
Total Liabilities
1.7B
Profitability
Net income Growth
2.3
Gross Margin
77.35%
Net Margin
33.82%
EBIT Margin
44.18%
EBITDA Margin
53.51%
Operating Margin
42.73%
Halozyme Therapeutics Stock (NASDAQ:HALO), Key Statistics
Halozyme Therapeutics Stock (NASDAQ: HALO) analysis, key statistics.
Valuation Measures
Enterprise Value
6.2B
Trailing P/E
22.48
Forward P/E
9.43
PE Ratio (TTM)
22.87
PEG Ratio (TTM)
- -
Price / Sales (ttm)
6.8
Price / Book (mrq)
33.37
Price / EBITDA
13.54
Enterprise Value / EBITDA (TTM)
15.93
Earnings Yield
4.45%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
1.14
Tangible Book value per share
-5.89
Total Liabilities (Quarterly)
1.7B
Total Assets
1.8B
Total Liabilities
1.7B
Profitability
Net income Growth
2.3
Gross Margin
77.35%
Net Margin
33.82%
EBIT Margin
44.18%
EBITDA Margin
53.51%
Operating Margin
42.73%
Halozyme Therapeutics Stock (NASDAQ:HALO), Key Statistics
Halozyme Therapeutics Stock (NASDAQ: HALO) analysis, key statistics.
Valuation Measures
Enterprise Value
6.2B
Trailing P/E
22.48
Forward P/E
9.43
PE Ratio (TTM)
22.87
PEG Ratio (TTM)
- -
Price / Sales (ttm)
6.8
Price / Book (mrq)
33.37
Price / EBITDA
13.54
Enterprise Value / EBITDA (TTM)
15.93
Earnings Yield
4.45%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
1.14
Tangible Book value per share
-5.89
Total Liabilities (Quarterly)
1.7B
Total Assets
1.8B
Total Liabilities
1.7B
Profitability
Net income Growth
2.3
Gross Margin
77.35%
Net Margin
33.82%
EBIT Margin
44.18%
EBITDA Margin
53.51%
Operating Margin
42.73%
Halozyme Therapeutics Stock (NASDAQ:HALO), Key Statistics
Halozyme Therapeutics Stock (NASDAQ: HALO) analysis, key statistics.
Valuation Measures
Enterprise Value
6.2B
Trailing P/E
22.48
Forward P/E
9.43
PE Ratio (TTM)
22.87
PEG Ratio (TTM)
- -
Price / Sales (ttm)
6.8
Price / Book (mrq)
33.37
Price / EBITDA
13.54
Enterprise Value / EBITDA (TTM)
15.93
Earnings Yield
4.45%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
1.14
Tangible Book value per share
-5.89
Total Liabilities (Quarterly)
1.7B
Total Assets
1.8B
Total Liabilities
1.7B
Profitability
Net income Growth
2.3
Gross Margin
77.35%
Net Margin
33.82%
EBIT Margin
44.18%
EBITDA Margin
53.51%
Operating Margin
42.73%